Cleveland Diagnostics (CDx) Inc.

About

Q&A

What is Cleveland Diagnostics' primary focus?

Cleveland Diagnostics is a precision oncology company focused on changing the shape of cancer detection.

What is Cleveland Diagnostics' flagship product?

Cleveland Diagnostics' first product is IsoPSA, a blood-based prostate cancer test indicated as an aid in the decision for prostate biopsy for men ≥ 50 years of age with elevated PSA levels.

What technology does Cleveland Diagnostics utilize for its diagnostics?

Cleveland Diagnostics utilizes its revolutionary IsoClear™ platform, which enables novel diagnostics based on a cancer-specific, protein structure-based assessment using easy to execute tests within the clinical lab setting.

When was Cleveland Diagnostics founded?

Cleveland Diagnostics was founded in 2013.

Who are the founders of Cleveland Diagnostics?

The founders of Cleveland Diagnostics are Arnon Chait, Chief Innovation Officer, and Boris Zaslavsky, Chief Scientific Officer.

Who is the current CEO of Cleveland Diagnostics?

Michael Iskra was appointed Chief Executive Officer of Cleveland Diagnostics in January 2026.

What is Cleveland Clinic's relationship with Cleveland Diagnostics?

Cleveland Clinic co-founded Cleveland Diagnostics and is a shareholder, holding a minority stake.

Which sectors does Cleveland Diagnostics operate in?

Cleveland Diagnostics operates in the Healthcare, Biotechnology, and Medical Diagnostics sectors, with a focus on Oncology and Prostate Cancer.

Team · 12

Arnon Chait

Founder · Chief Innovation Officer

Boris Zaslavsky

Founder · Chief Scientific Officer

Michael Iskra

Chief Executive Officer

Aimee Kestranek

Chief Operating Officer

Bob Rochelle

Chief Commercial Officer

Mark Stovsky

Chief Medical Officer

Jack Kenny

Chair of the Board

Dara Grantham Wright

CEO, Madison Medical (Board Member)

Noel Jee

Partner, Novo Holdings (Board Member)

Rich Ramko

Board Member

Joseph Rich

Managing Partner, Innovations and Ventures, Cleveland Clinic (Board Member)

Sameer Rohatgi

Partner, Lyfe Capital (Board Member)

Sectors & technology